Convenient Access to Treatment Since 1997 - Axios

Access to Treatment

Enabling patients to complete their full course of treatment through Axios-Partnered Patient Assistance Programs


What is Access to Treatment (ATT) Solutions? With the aid of our proprietary, validated tools and methodologies, Axios International, collaborates with stakeholders, including healthcare providers, physicians, pharmacists, multinational pharmaceutical companies, governments, charities, NGOs, distributors and insurance companies, to design and implement patient affordability programs that maximize medical benefits and financial sustainability.

Our partnered programs, designed with access to treatment in mind, incorporate various innovative financial models customized to the needs of individual patients, specific countries and products. Expanding beyond the general Fixed Schemes support, some of these models include Tiered Cost-Sharing Support, Co-Pay Voucher Support, Hybrid Managed Entry Agreements, and Direct to Institution Support, in addition to our value-added service: On-Time Access to Treatment (short-term financing) support. After determining the eligibility of the patients and determining their coverage status, we design and implement a program model unique to their financial means.

Thanks to our Program Partners and Clients, we have more than 213 active PAPs in Southeast Asia, Europe, the Middle East, Africa, and Latin America focusing on a variety of medical specialties, including cardiology, dermatology, pulmonology, rheumatology, gastroenterology, hematology, immunology, rare diseases, neurology, oncology, ophthalmology, and psychiatry.

Our approach to managing collaborative Patient Assistance Programs (PAPs)

Set up and implemented with carefully curated sustainable access solutions that help patients overcome their affordability barriers, Axios International-partnered PAPs provide equitable and affordable access to diagnosis, and treatment, assisting patients in overcoming financial challenges and help complete their full treatment course. What’s unique about the PAPs we manage is our approach to assessing patients' financial eligibility using Axios’ proprietary Patient Financial Eligibility Tool (PFET) and the 360-degree support we provide to patients throughout their treatment journey.

Determining the coverage status of a patient

The coverage status of a patient is a vital factor in determining their eligibility for Axios International’s Partnered-Patient Assistance Programs (PAPs) and avail access to treatment solutions. The coverage categories include:

  • Fully covered patient: Not financially eligible for the program
  • Medical insurance with co-payment: Eligible for Co-Pay Voucher Support
  • Medical insurance with budget limitation that does not cover the full treatment cost, or medical insurance with no coverage for the treatment, or No medical insurance available: Eligible for Tiered Cost-Sharing Support

Financially sustainable and innovative cost-sharing models:

Our innovative cost-sharing models are designed to enhance patients’ access to treatment. The access programs we manage are tailored to specific country, product, and patient requirements, incorporating a diverse range of access models. This includes:

- Tiered Cost-sharing Support:

Patients contribute to treatment costs based on their financial assessment results. The cost is shared between patients and multi-payers, including pharmaceutical companies, and potentially other payers such as charities, governments, insurers and more. The calculation of tiered cost-sharing is done for the complete treatment plan per medication per patient. It reduces the financial burden on the patient and enables them to complete their full course of treatment.

- Co-pay Voucher Support:

This model covers patients ‘non-reimbursed co-pay’ of medication and issues Co-pay vouchers for them to complete their full course of treatment as prescribed. The key advantage is that these vouchers cover the minimal co-pay contributions, ensuring patients receive a full treatment course.

- On-Time Access to Treatment (Short-term financing/ Microfinancing) Support:

As a Value-Added Service (VAS), On-Time Access to Treatment support is designed to assist patients in emergency needs to address cash flow issues. Implemented to complement the existing access to treatment solutions, through this model, Axios facilitates patients with immediate access to treatment while awaiting reimbursement from funding resources. What’s unique about this value-added support is that it not only provides timely assistance to patients but also facilitates the option to repay the funds fully or partially in instalments with zero interest and/or receive a Free of Charge (FOC) treatment based on their financial means.

- Hybrid Managed Entry Agreement (HMEA):

This innovative model involves cost-sharing for a product between multiple payers and the product manufacturer based on agreed-upon medical and patient health outcomes. Axios International collaborates with pharmaceutical companies, hospitals, and regulators to make registered medications available and accessible to patients. The cost of medication is divided among multi-payers, either determined by treatment provision or a pay-for-outcomes basis. The benefits include improved access to innovative medications for long-term rare diseases and independent evaluation of treatment impact by physicians.

- Direct to Institution Support:

This support mechanism facilitates patient access to high-quality specialty medications in countries where the product is not registered, minimizing import risks, especially for rare disease medications. Axios International directly collaborates with hospitals to make these medications accessible and available. With this, we provide medication access for patients undergoing treatment within the institution.

Patient Financial Eligibility Tool (PFET)
A cornerstone of Axios’ treatment access solutions, PFET is a one-of-a-kind tool developed by Axios to accurately determine how much help a patient needs to afford their full course of treatment. It can be used for both high and low cost products.
  • Improved accuracy. It is the only tool in the market today that takes into consideration country-specific income, assets and standard of living to improve the accuracy of assessment results in countries where informal economies often prevail.

  • Widely used. 30,000+ patients have been assessed using PFET in more than 20 countries.

  • Highly accepted. 90%+ of patients choose to undergo the assessment when asked.
  • Easy to scale and customized. Can be easily scaled and tailored to new countries, disease areas and medications.

  • Validated. PFET has been proven to effectively assess patients’ ability to pay in two studies published in Population Health Management and the Journal of Comparative Effectiveness Research.

Experience and Case Studies